DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-0002

March 31, 2016

Corin USA Limited
Ms. Diana L. Nader-Martone
Regulatory Affairs Associate
5670 West Cypress Street, Suite C
Tampa, Florida 33607

Re: K153772
Trade/Device Name: Corin TriFit TS Hip
Regulation Number: 21 CFR 888.3353
Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis
Regulatory Class: Class II
Product Code: MEH, LZO, KWL, KWY
Dated: December 30, 2015
Received: December 31, 2015

Dear Ms. Nader-Martone:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson -S

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.

510(k) Number *(if known)*
K153772

Device Name
Corin TriFit TS Hip

Indications for Use *(Describe)*
The indications for the Corin TriFit TS Hip as a total hip arthroplasty, and when used in combination with a Corin hemi arthroplasty head, as a hip hemi-arthroplasty, include:

- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis
- Correction of functional deformity
- Treatment of non-union and femoral neck fractures
- Developmental dysplasia of the hip (DDH) or congenital dysplasia of the hip (CDH)

The TriFit TS Hip is intended for cementless use only.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3. 510(K) SUMMARY

1. **Applicant/Sponsor:** Corin USA
   Distributor 5670 W. Cypress Street
   Suite C
   Tampa, Florida 33607
   Establishment Registration No.: 1056629

2. **Contact Person:** Diana L. Nader-Martone
   Regulatory Affairs Associate
   Corin USA
   813-977-4469
   diana.nader-martone@coringroup.com

   Kathy Trier
   VP Global Regulatory and Clinical Affairs
   Corin USA
   813-977-4469
   kathy.trier@coringroup.com

3. **Date:** March 30, 2016

4. **Proprietary Name:** Corin TriFit TS Hip

5. **Common Name:** Hip Prosthesis

6. **Product Code(s):** MEH**,** LZO, KWL, KWY

7. **Classification Name:**
   21 CFR 888.3353 – Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis
   21CFR 888.3360 – Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis
   21CFR 888.3390 – Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis

8. **Legally Marketed Devices to which Substantial Equivalence is claimed:**
   - Corin TriFit TS Hip Stem (K121563)

9. Device Description:

The Corin TriFit TS Hip is a double tapered-wedge blade stem design manufactured from Ti6Al4V Titanium alloy (ASTM F-136-08) with a layer of commercially pure titanium (BS ISO 5832-2: 1999) and calcium phosphate (BONIT®) coating (ASTM F1609-08) applied. The TriFit TS Hip is available in 11 sizes in standard and lateralized offsets with a 127° CCD angle. The device is intended to be used with Corin 12/14 modular taper heads.

The TriFit TS Hip is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components.

The Corin TriFit TS Hip Stem was originally cleared in K121563. The purpose of this submission is to modify the labeling to remove an indication from the indications for use for the TriFit TS Hip Stem, for clarity to ensure safe or effective use. The design and compatible components for use with the Corin TriFit TS Hip stem subject of this submission are identical to that of the predicate device K121563.

10. Intended Use / Indications:

The indications for the Corin TriFit TS Hip as a total hip arthroplasty, and when used in combination with a Corin hemi arthroplasty head, as a hip hemi-arthroplasty, include:

- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis
- Correction of functional deformity
- Treatment of non-union and femoral neck fractures
- Developmental dysplasia of the hip (DDH) or congenital dysplasia of the hip (CDH)

The TriFit TS Hip is intended for cementless use only.

11. Summary of Technologies / Substantial Equivalence:

The TriFit TS Hip Stem subject of this submission is identical to the predicate TriFit TS Hip Stem (K121563) in design, materials, coating, sizes and similar in terms of intended use/indications for use. Based on these similarities, Corin believes that the TriFit TS Hip Stem is substantially equivalent to the predicate device.

12. Non-Clinical Testing:

A comparison of indications for use and contraindications demonstrate substantial equivalence

13. Clinical Testing:

Clinical testing was not necessary in this Traditional 510(k).